<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="100928">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02035059</url>
  </required_header>
  <id_info>
    <org_study_id>EKBB195/13</org_study_id>
    <nct_id>NCT02035059</nct_id>
  </id_info>
  <brief_title>Predictability of Gestational Diabetes Mellitus in First and Second Trimester</brief_title>
  <acronym>GDMPredict</acronym>
  <official_title>Predictability of Gestational Diabetes Mellitus in First and Second Trimester, Using Novel Biomarkers, and the Development of New Biomarkers by Quantitative Proteomic Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Basel Women’s University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Basel Women’s University Hospital</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is, if an early oral glucose tolerance test combined with
      maternal history, condition and multiple biomarker analysis can be used to detect
      gestational diabetes mellitus in the first trimester (12-14 weeks of gestation).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is the investigators' aim to prospectively examine an extended form of the current 1st
      trimester screening test for the detection of foetal aneuploidy, in order to ascertain
      whether this can also be used for the detection of patients at-risk for gestational diabetes
      mellitus. For this purpose the investigators will include a combination of new markers in a
      multiplex bio-array manner in conjunction with an early oral glucose tolerance test.  A
      nested case-control proteomic analysis will be performed in a retrospective manner at the
      completion of this study in order to develop more specific biomarker panels.

      The primary outcome will be development of gestational diabetes mellitus in the second or
      third trimester.

      The secondary endpoints are the delivery outcome, neonatal morbidity, neonatal mortality,
      maternal morbidity and costs.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Development of Gestational Diabetes in second/third trimester</measure>
    <time_frame>24-28 weeks of gestation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Development of gestational diabetes in 24-28 weeks of gestation by pathological values in oral glucose tolerance test 75g</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Pregnancy</condition>
  <condition>Gestational Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Women with/without gestational diabetes</arm_group_label>
    <description>Women with/without gestational diabetes diagnosed by clinically routine 75 g oral glucose tolerance testing</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Pregnant Women
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy singleton pregnancies

          -  Women at least 18 years old and not under guardianship

        Exclusion Criteria:

          -  Maternal diseases like hypertension, diabetes mellitus and chronic disease, known
             infection like hepatitis or human immunodeficiency virus

          -  Maternal history of hypertensive diseases in previous pregnancy and now under
             prophylactic acetylsalicylate treatment

          -  Foetal genetic, chromosomal or intervention-requiring morphologic abnormalities
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evelyn Huhn, MD</last_name>
    <role>Study Director</role>
    <affiliation>Women`s Hospital, University Basel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irene Hösli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Women`s Hospital, University Basel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evelyn Huhn, MD</last_name>
    <phone>+41615565144</phone>
    <email>evelyn.huhn@usb.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Women`s Hospital, University Basel</name>
      <address>
        <city>Basel</city>
        <state>Basel-Stadt</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Evelyn Huhn, MD</last_name>
      <phone>+41615565144</phone>
      <email>evelyn.huhn@usb.ch</email>
    </contact>
    <investigator>
      <last_name>Irene Hösli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huhn Evelyn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 13, 2014</lastchanged_date>
  <firstreceived_date>January 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral Glucose Tolerance Test</keyword>
  <keyword>Fibronectin</keyword>
  <keyword>Adiponectin</keyword>
  <keyword>Copeptin</keyword>
  <keyword>Cortisol</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
